Altrafin AG Purchases New Stake in Novo Nordisk A/S $NVO

Altrafin AG purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 175,183 shares of the company’s stock, valued at approximately $8,913,000. Novo Nordisk A/S makes up approximately 2.8% of Altrafin AG’s investment portfolio, making the stock its 14th biggest holding.

A number of other institutional investors have also recently modified their holdings of the business. Capital International Investors boosted its stake in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of Novo Nordisk A/S by 6.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after buying an additional 969,916 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after buying an additional 717,719 shares in the last quarter. Morgan Stanley boosted its stake in shares of Novo Nordisk A/S by 3.5% in the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after buying an additional 428,660 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Novo Nordisk A/S by 1.0% in the third quarter. State Street Corp now owns 6,106,836 shares of the company’s stock valued at $340,125,000 after buying an additional 59,153 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $43.90 on Friday. The stock has a market cap of $196.02 billion, a price-to-earnings ratio of 10.31, a price-to-earnings-growth ratio of 3.92 and a beta of 0.78. The business has a fifty day moving average of $42.28 and a 200-day moving average of $46.00. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, analysts predict that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

NVO has been the topic of a number of analyst reports. Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target on the stock. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.